Bruce L. Zuraw, M.D here ., Paula J. Busse, M.D., Martha Light, M.D., Joshua Jacobs, M.D., William Lumry, M.D., James Baker, M.D., Timothy Craig, D.O., J. Andrew Grant, M.D., David Hurewitz, M.D., Leonard Bielory, M.D., William. E. Cartwright, M.D., Majed Koleilat, M.D., Walter Ryan, D.O., Oren Schaefer, M.D., Michael Manning, M.D., Pragnesh Patel, M.D., Jonathan A. Bernstein, M.D., Roger A. Friedman, M.D., Robert Wilkinson, M.D., David Tanner, M.D., Gary Kohler, M.D., Glenne Gunther, M.D., Robyn Levy, M.D., James McClellan, M.D., Joseph Redhead, M.D., David Guss, M.D., Eugene Heyman, Ph.D., Brent A. Blumenstein, Ph.D., Ira Kalfus, M.D., and Michael M.
Adverse events were graded ranging from 1 to 4, with 1 indicating mild events and 4 indicating potentially life-threatening events, according to a severity scale as adopted in December 2004 by the Division of Helps at the National Institutes of Wellness. The data and safety monitoring board met on January 29, 2008, for the first efficacy review. Protocol prespecified time-to-event distributions were presented general and within each screening HIV-1 RNA stratum. When data in the four groups were combined and analyzed as two organizations and with S-Plus software, edition 6 . Results Study Patients From September 2005 to November 2007 A total of 1858 eligible individuals were enrolled in the study.